Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Senzime AB ( (SE:SEZI) ) is now available.
Senzime AB has been granted a new U.S. patent for its TetraGraph system, which enhances the system’s capabilities by improving the quality of electromyography signals. This patent strengthens Senzime’s competitive position in the neuromuscular monitoring field, highlighting their commitment to innovation and patient safety.
More about Senzime AB
Senzime AB is a company operating in the medical technology industry, focusing on neuromuscular monitoring solutions. Their primary product, the TetraGraph system, is used in operating rooms to enhance patient safety by allowing precise dosing of neuromuscular blocking agents and ensuring safe recovery from anesthesia.
Average Trading Volume: 327,027
Current Market Cap: SEK799.8M
See more data about SEZI stock on TipRanks’ Stock Analysis page.